Cell and Gene Therapy Market to Grow by USD 6.56 Billion (2024-2028), Driven by Rising Prevalence of Chronic Diseases, AI-Powered Report Explores Market Evolution – Technavio | PR Newswire [Video]

NEW YORK, Nov. 13, 2024 /PRNewswire/ — Report on how AI is driving market transformation – The global cell and gene therapy market size is estimated to grow by USD 6.56 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 14.76% during the forecast period. Increasing prevalence of chronic diseases is driving market growth, with a trend towards strategic alliances. However, high cost and failure rate in clinical trials poses a challenge.Key market players include Alnylam Pharmaceuticals Inc., Amgen Inc., Biogen Inc., bluebird bio Inc., Bristol Myers Squibb Co., Castle Creek Biosciences Inc., CORESTEM Inc., Cytori Therapeutics Inc., Dendreon Pharmaceuticals LLC, Ferring BV, Gilead Sciences Inc., Helixmith Co. Ltd., Human Stem Cells Institute, JCR Pharmaceticals Co. Ltd., Kolon TissueGene Inc., Novartis AG, Orchard Therapeutics Plc, Pfizer Inc., Sibiono GeneTech Co. Ltd., and Vericel Corp..

AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth …